Aktienanalyse zu iTonic Holdings Ltd (ITOC)ITOCiTonic Holdings Ltd

iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others. It operates in the Healthcare sector.

iTonic Holdings Ltd is not a good buy right now due to significant risks and negative catalysts. The stock has a current price of 0.32, and it has experienced a staggering 64.90% decline year-to-date. Additionally, a class action lawsuit has been filed against the company, alleging securities fraud, which adds to the uncertainty surrounding the stock.